

# KOBO BIOTECH LIMITED

(Formerly known as Avon Lifesciences Limited)

E-mail: info@avonlifesciences.com • Website : www.avonlifesciences.com

(CIN : L24110TG1993PLC016112)

Asst. General Manager,  
Dept. of Corporate Services.  
Bombay Stock Exchange Limited,  
14th Floor, P.J.Towers, Dalal Street, Fort,  
Mumbai: 400 001

8<sup>th</sup> November, 2021

Dear Sir/ Madam,

Scrip Name: Kobo Biotech Limited, Scrip Code: 531541

**Sub: OUTCOME OF THE BOARD MEETING: Unaudited Financial results for the Quarter and half year ended 30<sup>th</sup> September, 2021.**

This is to inform you that the Board of Directors of Kobo Biotech Limited at their meeting held today i.e. on Monday, 8<sup>th</sup> November, 2021 inter alia approved the Unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2021 alongwith the Limited review report of statutory auditor thereon.

Please find enclosed a copy of the unaudited Financials along with Limited Review report from the Statutory Auditors.

The above-referred meeting was commenced at 3:00 p.m. and concluded at 4:30 p.m.

The above is pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, for your information and record.

Thank you,  
For Kobo Biotech Limited

*J. M. Patel.*  
Jignesh Patel  
Company Secretary





CA. Mukesh Mehta  
B. Com. F.C.A.  
CA. Shantilal Jain  
B. Com. F.C.A.  
CA. Prince Kothari  
B. Com. A.C.A.

**N G JAIN & CO**  
**CHARTERED ACCOUNTANTS**

320, Hammersmith Ind. Premises Co-op. Soc. Ltd., Naryan Pathare Marg, Off Sitladevi Temple Road, Mahim (West),  
Mumbai - 400 016 Tel.: 02265010393 / 9082687144

### **LIMITED REVIEW REPORT**


**Independent Auditor's Review Report on Quarter and Half Year end Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,  
**Board of Directors of  
Kobo Biotech Limited  
Mumbai.**

We have reviewed the accompanying statement of unaudited financial results of **Kobo Biotech Limited** ("the Company") for the quarter and Half year ended 30th September 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



E-mail : [info@ngjain.com](mailto:info@ngjain.com), [ngjain2002@gmail.com](mailto:ngjain2002@gmail.com), web : [ngjain.com](http://ngjain.com)


In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) Are presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements)Regulation.2015; and
- (ii) Give a true and fair view in conformity with the aforesaid accounting standards and other accounting principles generally accepted in India of the net Loss and other financial information of the company for the quarter and Half year ended 30<sup>th</sup> September, 2021.

**For N G JAIN & Co**  
**Chartered Accountants**



**Prince Kothari**  
**Partner**  
**Membership No.: 155819**  
**FRN No.: 103941W**  
**Place: Mumbai**  
**Date: 08<sup>th</sup> November 2021**  
**UDIN NO: 21155819AAAACT9323**



**KOBO BIOTECH LIMITED**  
(FORMERLY AVON LIFESCIENCES LIMITED)

CIN: L24110TG1993PLC016112

Regd. Office : 505, Plot No.193 & 193/1, Chandi Nilayam, Samatha Nagar, Bhagyanagar 3rd Phase, Kukatpally, Hyderabad - 500 085  
Corp. Office : H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai - 400 072

**Statement of Unaudited Results for the quarter and Half Year ended 30th September, 2021**

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Half Year Ended		Year Ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations	0.00	0.00	0.00	0.00	0.00	0.00
II	Other Income	0.00	1.66	0.00	1.66	3.59	3.59
III	<b>Total Income (I+II)</b>	<b>0.00</b>	<b>1.66</b>	<b>0.00</b>	<b>1.66</b>	<b>3.59</b>	<b>3.59</b>
IV	<b>Expenditure</b>						
	(a) Cost of raw material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Employee benefits expense	49.04	5.99	46.89	55.03	90.42	139.27
	(d) Finance Cost	13.45	0.00	360.00	13.45	724.00	1,084.07
	(e) Depreciation and Amortisation expenses	102.97	135.15	142.09	238.12	282.65	563.70
	(f) Exchange( Gain)/Loss	0.00	0.00	0.00	0.00	0.00	58.34
	(g) Other Expenses	20.87	20.28	19.85	41.15	36.47	81.34
	<b>Total Expenses</b>	<b>186.33</b>	<b>161.42</b>	<b>568.83</b>	<b>347.75</b>	<b>1,133.54</b>	<b>1,926.72</b>
V	<b>Profit (Loss) before Exceptional Items and Tax (III-IV)</b>	<b>(186.33)</b>	<b>(159.76)</b>	<b>(568.83)</b>	<b>(346.09)</b>	<b>(1,129.95)</b>	<b>(1,923.13)</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit (Loss) before Tax (V-VI)</b>	<b>(186.33)</b>	<b>(159.76)</b>	<b>(568.83)</b>	<b>(346.09)</b>	<b>(1,129.95)</b>	<b>(1,923.13)</b>
VIII	Tax expenses						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Net Profit (Loss) after tax (VII-VIII)</b>	<b>(186.33)</b>	<b>(159.76)</b>	<b>(568.83)</b>	<b>(346.09)</b>	<b>(1,129.95)</b>	<b>(1,923.13)</b>
X	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>(186.33)</b>	<b>(159.76)</b>	<b>(568.83)</b>	<b>(346.09)</b>	<b>(1,129.95)</b>	<b>(1,923.13)</b>
XII	Paid-up equity share capital	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50
XIII	Other Equity						(13,102.72)
XIV	<b>Earnings Per Share (Basic and Diluted)</b>	<b>(0.78)</b>	<b>(0.67)</b>	<b>(2.39)</b>	<b>(1.45)</b>	<b>(4.74)</b>	<b>(8.07)</b>

**Notes:**

Notes :	
1	The above audited standalone financial results, prepared in accordance with the Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 and guidelines issued by the Securities and Exchange Board of India, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th November, 2021.
2	The Company operates only in one Business Segment i.e. manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs.
3	Due to no operational activities at the Company for the past few years, the Employee benefit expenses for the quarter is considered only for the Employees who are reporting to work. Similarly, the interest cost for the quarter is not being provided for, as majority of the loans have been assigned to a leading ARC and for the remainder of the secured loans, the company has entered into settlement plan with one such lender and is under discussion with the other lender for settlement.
4	The number of investor complaints at the beginning and pending at the end of the Quarter were Nil.
5	Figures for the quarter ended 31st March are the balancing figures between the audited figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year, which were subjected to limited review
6	Figures of the previous periods have been regrouped / rearranged wherever considered necessary.

By order of the Board  
For Kobo Biotech Limited



✓

**Ajit Kamath**  
Director

Mumbai  
08-Nov-21

**KOBO BIOTECH LIMITED**  
(FORMERLY AVON LIFESCIENCES LIMITED)  
CIN: L24110TG1993PLC016112

Regd. Office : 505, Plot No.193 & 193/1, Chandi Nilayam, Samatha Nagar, Bhagyanagar 3rd Phase, Kukatpally, Hyderabad - 500 085  
Corp. Office : H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai - 400 072

**BALANCE SHEET AS AT SEPTEMBER 30, 2021**

(Amount in INR Lakhs)

Particulars	As at September 30, 2021 (Unaudited)	As at March 31, 2021 (Audited)
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant and Equipment	4,388.41	5,690.69
(b) Capital Work-in-Progress	0.00	225.07
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible Assets Under Development		0.00
(g) Financial Assets		
(i) Investments	1,219.30	1,219.30
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.51	0.51
(iv) Others	0.00	0.00
(h) Deferred Tax Asset (Net)	0.00	0.00
(i) Other Non-Current Assets	0.00	0.00
	<b>5,608.22</b>	<b>7,135.57</b>
<b>Current assets</b>		
(a) Inventories	1,804.05	5,327.86
(b) Financial Assets		
(i) Investments	0.00	0.00
(ii) Trade Receivables	6,086.51	9,247.16
(iii) Cash and Cash Equivalents	8.46	151.70
(iv) Bank Balances Other than (iii) above	4.29	4.29
(v) Loans	79.26	79.26
(vi) Others	0.00	0.00
(c) Current Tax Assets (Net)	571.60	571.47
(d) Other Current Assets	507.51	541.49
	<b>9,061.68</b>	<b>15,923.23</b>
<b>TOTAL</b>	<b>14,669.90</b>	<b>23,058.80</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	2,382.50	2,382.50
(b) Other Equity	(13,448.81)	(13,102.72)
	<b>(11,066.31)</b>	<b>(10,720.22)</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	3,353.40	3,353.40
(ii) Trade Payables		
Micro, Small and Medium Enterprises	0.00	0.00
Others	0.00	0.00
(iii) Other Financial Liabilities	0.00	0.00
(b) Provisions	210.84	210.84
(c) Deferred Tax liabilities (Net)	299.01	299.01
(d) Other Non-Current Liabilities	0.00	0.00
	<b>3,863.25</b>	<b>3,863.25</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	10,172.92	17,472.87
(ii) Trade Payables	6,432.32	6,045.10
Micro, Small and Medium Enterprises	0.00	0.00
Others	0.00	0.00
(iii) Other Financial Liabilities	5,247.43	6,360.44
(b) Other Current Liabilities	20.29	37.36
(c) Provisions	0.00	0.00
(d) Current Tax Liabilities (Net)	0.00	0.00
	<b>21,872.96</b>	<b>29,915.77</b>
<b>TOTAL</b>	<b>14,669.90</b>	<b>23,058.80</b>

For Kobo Biotech Limited



Mumbai  
8-Nov-21

Ajit Kamath  
Director

**CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th September, 2021**

**(Amount in INR Lakhs)**

<b>Particulars</b>	<b>For the half year ended 30th Sept, 2021</b>	<b>For the year ended 31st March, 2021</b>
<b>A. Cash Flow from Operating Activities</b>		
Net Profit before tax and extraordinary items	(346.09)	(1,923.13)
<b>Adjustments for</b>		
Depreciation	238.12	563.70
Interest & Financial Charges	13.45	1,084.07
<b>Operating Profits before Working Capital Changes</b>	<b>(94.52)</b>	<b>(275.36)</b>
(Increase) / Decrease in Inventories	3,523.81	
(Increase) / Decrease in Debtors	3,160.65	81.42
(Increase) / Decrease in Loans & Advances	33.86	72.75
Increase / (Decrease) in Current Liabilities	(742.86)	408.34
Increase / (Decrease) in Cash Credit Loan	(7,299.96)	1,080.00
<b>Cash Generated from Operations</b>	<b>(1,419.02)</b>	<b>1,367.15</b>
Income Tax		
<b>Net Cash flow from operating Activities (A)</b>	<b>(1,419.02)</b>	<b>1,367.15</b>
<b>B. Cash Flow from Investing Activities</b>		
Fixed Assets	1,289.22	-
<b>Net Cash Used in Investing Activities (B)</b>	<b>1,289.22</b>	<b>-</b>
<b>C. Cash Flow from Financing Activities</b>		
Change in Share capital		-
Change in security Premium		-
Change in Money receivedd against Share warrants		-
Change in long term borrowings	0.00	(139.88)
Interest & Financial Charges	(13.45)	(1,084.07)
<b>Net Cash inflow from Financing Activities (C)</b>	<b>(13.45)</b>	<b>(1,223.95)</b>
<b>Net Increase/(Decrease) in Cash Flow (A+B+C)</b>	<b>(143.25)</b>	<b>143.20</b>
Opening Balance of Cash and Cash Equivalent	155.98	12.78
<b>Closing Balance of Cash and Cash Equivalent</b>	<b>12.73</b>	<b>155.98</b>

**For KOBO BIOTECH LIMITED**



Mumbai  
08-11-2021

**Ajit Kamath**  
**Director**